- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% Ars Technica
- Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report The New York Times
- Experimental mRNA vaccine cuts risk melanoma returns by 42% CNN
- Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media WSJ
- Moderna stock crashes as leaked melanoma data threatens its record August rally Yahoo Finance